Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI
We recently published a list of 15 Stocks That Stole The Show Last Week.
Recursion Pharmaceuticals Inc. (RXRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 34,815,502 | $184,174,004 | +8% | 1.84% |
| 2. | MIC Capital Partners Mubadala Investment | 9,644,032 | $51,016,935 | -1% | 10.39% |
| 3. | Citadel Investment Group Ken Griffin | 2,655,711 | $14,048,711 | -4% | 0% |
| 4. | Laurion Capital Management Benjamin A. Smith | 1,547,407 | $8,185,783 | -38% | 0.21% |
| 5. | 1,359,885 | $7,193,792 | +4% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.82 | 66,822 | Large Shareholder | 12,985,927 | 2023-03-02 | Filing | |
| $7.94 | 48,867 | Large Shareholder | 12,919,105 | 2023-03-01 | Filing | |
| $7.97 | 815 | Large Shareholder | 12,870,238 | 2023-02-28 | Filing | |
| $7.69 | 52,500 | Large Shareholder | 12,869,423 | 2023-02-27 | Filing | |
| $7.64 | 109,118 | Large Shareholder | 12,816,923 | 2023-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.04 | 138,574 | Officer, Director | 1,117,450 | 2025-03-27 | Filing | |
| $6.37 | 20,000 | Officer, Director | 1,256,024 | 2025-03-06 | Filing | |
| $6.58 | 20,000 | Officer, Director | 1,256,024 | 2025-03-05 | Filing | |
| $8.12 | 20,000 | Officer, Director | 1,273,156 | 2025-02-06 | Filing | |
| $7.68 | 20,000 | Officer, Director | 1,273,156 | 2025-02-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 32,287,977 | $170,803,398 | 0% | |
| 2. | 24,393,015 | $129,039,050 | 0.11% | |
| 3. | 23,506,589 | $124,349,857 | 0% | |
| 4. | 14,667,491 | $77,591,027 | 0.26% | |
| 5. | 13,434,171 | $71,066,765 | 100% |
News See All
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of 10 Stocks Are Dominating Like Wall Street Titans. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today
We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?
We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.
Did Jim Cramer Nail or Miss These 11 Stock Predictions?
During the most recent episode of Mad Money, which aired on Tuesday the 27th of May, Jim Cramer opened with a passionate defense of the artificial intelligence boom, warning viewers not to dismiss the...
10 Most Popular AI Stocks to Avoid Now
Over the last two years, artificial intelligence has been the central theme driving equities to record highs amid expectations that its technological innovations will change how the world works.
13 Best Artificial Intelligence Stocks Under $50 to Buy Now
On May 8, Dan Ives of Wedbush Securities joined CNBC's 'Squawk on the Street' to discuss his bullish outlook on the AI sector and tech.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript May 5, 2025Recursion Pharmaceuticals, Inc. misses on earnings expectations.
Did Jim Cramer Nail All These 9 Stock Predictions?
“When you see a grizzly bear in Yellowstone National Park, you call a park ranger because these bears are dangerous… but the grizzlies turn into teddy bears when the rangers come, and you can’t ...
Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks
In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer suggested the recent tariffs might not simply be about economic leverage.
Billionaire Hedge Funds
